Shilpa Pharma Lifesciences Limited, Unit-1, ANVISA Audit from Brazil

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

SHILPAMED · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.6%Reaction day

₹447.50

prior close

₹450.00

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-0.5%-0.1% vs market

Pharmaceuticals peers, median of 150sector-0.4%-0.2% vs sector

On the reaction day the stock moved 0.1 pts less than Nifty Microcap 250 and 0.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.6

10m

+0.6

15m

+1.6

30m

+1.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.6-0.5-0.1-0.4-0.2

Next day

-4.1-0.6-3.5-0.9-3.2

-5.0-0.1-4.9-0.6-4.4

-2.4+0.3-2.6-0.9-1.4

-0.2-0.2+0.0-1.2+0.9

+0.6-0.1+0.7-0.3+0.9

+4.7+1.6+3.1+1.1+3.6

15d

-1.0-2.5+1.6-1.6+0.6

-7.9-4.2-3.7-4.7-3.2

-5.3-2.6-2.7-4.5-0.7

-17.9-3.7-14.2-5.4-12.5

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 150Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Shilpa Medicare's wholly-owned subsidiary, Shilpa Pharma Lifesciences Limited (Unit-1), successfully completed a GMP inspection by ANVISA, Brazil's health regulatory authority. The audit took place from June 30 to July 4, 2025, and concluded with no critical or major observations. Only minor procedural recommendations were noted, which the company plans to address through a CAPA plan within required timelines. This confirms the facility meets Brazilian GMP standards and can continue to supply pharmaceutical products to the Brazilian market.

Likely market impact

Positive for shareholders — successful clearance with no critical or major observations from a key international regulator (Brazil/ANVISA) supports uninterrupted exports to Latin America and reinforces the company's regulatory compliance track record. This typically strengthens credibility for further approvals and business from regulated markets.